Page 70 - Read Online

Page 8 of 9 Rosenzweig et al. J Cancer Metastasis Treat 2022;8:46 https://dx.doi.org/10.20517/2394-4722.2022.58

2016;35:e205-15. DOI PubMed
8. Sertkaya A, Birkenbach A, Berlind A, Eyraud J. Examination of clinical trial costs and barriers for drug development, In: Report
HHSP23337007T, Department of Health and Human Services (HHS): Washington USA. 2014.
9. Matrisian LM, Rosenzweig A, Moravek C, Duliege AM. Trends in pancreatic cancer clinical trials in the United States. Med Res Arch
2021. DOI
10. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med 2017;377:62-70.
DOI PubMed
11. Seligson ND, Knepper TC, Ragg S, Walko CM. Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging
cancer biology for precision medicine. Clin Pharmacol Ther 2021;109:334-42. DOI PubMed PMC
12. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med
2019;381:317-27. DOI PubMed PMC
13. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for
patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. DOI PubMed
14. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
2011;364:1817-25. DOI PubMed
15. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med
2013;369:1691-703. DOI PubMed PMC
16. Wang-gillam A, Li C, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer
after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 2016;387:545-57. DOI
PubMed
17. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in
patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 2017;389:1011-24.
DOI PubMed
18. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med
2018;379:2395-406. DOI
19. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med
2018;378:731-9. DOI PubMed PMC
20. Doebele RC, Drilon A, Paz-ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours:
integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-82. DOI PubMed PMC
21. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours
treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet
Oncol 2020;21:1353-65. DOI PubMed
22. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science
2017;357:409-13. DOI PubMed PMC
23. FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors, 2021. Available from:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-gxly-dmmr-advanced-
solid-tumors [Last accessed on 13 Oct 2022].
24. Salama AKS, Li S, Macrae ER, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E mutations: results of the NCI-
MATCH trial subprotocol H. J Clin Oncol 2020;38:3895-904. DOI PubMed PMC
25. Hendifar A, Blais EM, Wolpin B, et al. Retrospective case series analysis of RAF family alterations in pancreatic cancer: real-world
outcomes from targeted and standard therapies. JCO Precis Oncol 2021;5:PO. DOI PubMed PMC
26. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-
501. DOI PubMed PMC
27. Genome Atlas Research Network. Electronic address, Cancer genome atlas research network. integrated genomic characterization of
pancreatic ductal adenocarcinoma. Cancer Cell 2017;32:185-203.e13. DOI
28. Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following
molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 2020;21:508-18. DOI PubMed
PMC
29. Pishvaian MJ, Bender RJ, Halverson D, et al. Molecular profiling of patients with pancreatic cancer: initial results from the know your
tumor initiative. Clin Cancer Res 2018;24:5018-27. DOI PubMed
30. Aung KL, Fischer SE, Denroche RE, et al. Genomics-driven precision medicine for advanced pancreatic cancer: early results from the
COMPASS trial. Clin Cancer Res 2018;24:1344-54. DOI PubMed PMC
31. Chan-Seng-Yue M, Kim JC, Wilson GW, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during
tumor evolution. Nat Genet 2020;52:231-40. DOI
32. Dreyer SB, Jamieson NB, Cooke SL, et al. PRECISION-Panc: the next generation therapeutic development platform for pancreatic
cancer. Clin Oncol 2020;32:1-4. DOI PubMed
33. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting
of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100. DOI PubMed
34. Alexander BM, Ba S, Berger MS, et al. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin Cancer